Our mission is to provide an effective long-term solution for the global coronavirus challenge.

Highly potent broadly neutralizing antibodies offer the best possibility to resolve the current COVID19 pandemic while also preparing for future outbreaks of related viruses.

Our best-in-class broadly neutralizing antibodies can meet the current and future challenges posed by the spillover of coronaviruses into humans.

Our mission is to provide an effective long-term solution for the global coronavirus challenge.
Highly potent broadly neutralizing antibodies offer the best possibility to squelch the current COVID19 pandemic while also preparing for future outbreaks of related viruses.
Our best in class broadly neutralizing antibodies can meet the current and future challenges posed by the spillover of coronaviruses into humans.

Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.

We believe that COVID-19 will become an endemic disease requiring a variety of effective, safe and convenient treatment and preventative options for years to come. We aim to address COVID-19 and future potential coronavirus outbreaks by building a portfolio of antibodies with broadly neutralizing activity against multiple members of the coronavirus family. We are deploying a similar approach to address other respiratory viruses with high pandemic potential.

Our lead product candidate, ADG20, is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 as either a single or combination agent.

ADG20 is being evaluated in two, Phase 2/3 clinical trials:

The STAMP Trial for the treatment of COVID-19

The EVADE Trial for the prevention of COVID-19

We’re focused on making an impact on global health. Find a position that’s right for you.